Semax: Research Overview, Mechanism and Lab Handling

Semax is a synthetic seven-amino-acid peptide based on a fragment of adrenocorticotropic hormone (ACTH), modified so that it no longer acts as a stress hormone. It was developed in Russia, where it has been used in clinical practice, and it is widely studied in neuroscience research for its links to neurotrophic signaling and neuroprotection in experimental models. This guide covers what Semax is, the mechanisms studied, the main research areas and lab handling.

What is Semax?

Semax is a heptapeptide with the sequence Met-Glu-His-Phe-Pro-Gly-Pro. The first four residues come from ACTH(4-7), part of the ACTH(4-10) region that earlier research had associated with effects on attention and learning in animals, independent of the hormone's action on the adrenal glands. The last three residues, Pro-Gly-Pro, were added to slow breakdown by enzymes and extend the peptide's activity.

Because Semax lacks the parts of ACTH needed to stimulate cortisol release, it is studied for its central nervous system effects rather than hormonal ones. Modified forms such as N-acetyl Semax amidate also appear in the research literature.

Semax is one of several regulatory peptides developed in Russia, alongside the related anxiolytic peptide Selank. It is not an approved medicine in the US and is supplied by PRIME as a research compound.

How Semax works: mechanism studied in research

The mechanism of Semax is not fully mapped, and research points to several pathways rather than one receptor. Findings from cell and animal studies include:

• Neurotrophic signaling: Semax has been associated with increased expression of brain-derived neurotrophic factor (BDNF) and its receptor TrkB in rodent brain regions such as the hippocampus and cortex.
• Gene expression after injury: in rodent models of cerebral ischemia, Semax has been linked to changes in genes involved in inflammation, blood vessel function and neurotransmission.
• Neurotransmitter systems: animal work suggests effects on dopaminergic and serotonergic signaling.
• Melanocortin receptors: as an ACTH fragment, Semax has been examined for interactions with melanocortin receptors, though how much this explains its effects remains an open question.

BDNF is central to synaptic plasticity, neuron survival and learning, which is why the BDNF findings anchor much of the current interest in Semax. Researchers should note that much of the literature comes from a limited number of research groups, and independent replication in different models remains valuable.

Why Semax is studied as a research tool

Semax offers researchers a short, defined peptide that can be used to probe neurotrophic signaling without the hormonal effects of the full ACTH molecule. That separation is useful for asking whether behavioral or molecular changes in a model come from central melanocortin-related and neurotrophic pathways rather than from the adrenal stress response. Its small size also makes it practical to synthesize, test for identity and compare with modified analogs.

Another feature of interest is the Pro-Gly-Pro tail. This short motif, shared with Selank, has itself been studied for effects on stability and on biological activity, and comparing peptides that carry it with those that do not is one way researchers try to separate the roles of the core sequence and the stabilizing extension. Semax is also frequently used as a comparison compound in studies of other neuroactive peptides, which is why consistent, well-characterized material matters for cross-study comparison.

Areas of research

Semax has been studied in cell culture, animal models and clinical settings outside the US. Research areas include:

• Cerebral ischemia and stroke models: gene expression, tissue injury and recovery in rodents
• Learning and memory: behavioral tasks measuring attention and memory in animal models
• Neurotrophic factor biology: BDNF and TrkB expression and signaling
• Optic nerve and retinal research: neuroprotection in experimental models of optic nerve damage
• Stress and neuroinflammation: behavioral and molecular responses to stress in rodents

Semax key facts table

Handling and storage in the lab

Good handling is part of good data in peptide neuroscience, where small differences in material can shift behavioral results. Semax is supplied as a lyophilized powder. Short peptides like this are fairly robust when dry but degrade faster once in solution. General lab handling points:

• Equilibrate: allow the vial to reach room temperature before opening to reduce condensation.
• Reconstitute gently: for lab use, reconstitute with bacteriostatic water or a buffer suited to the assay, adding it slowly down the vial wall and swirling rather than shaking.
• Dry storage: keep sealed vials cold, dry and dark. A freezer suits long-term storage.
• Solution storage: refrigerate reconstituted material, protect it from light and avoid repeated freeze-thaw cycles. Aliquoting helps.
• Documentation: label every vial with compound, diluent, date and lot number.
• Consistency: use the same diluent and preparation routine across all groups in a study so that differences reflect the experimental variable rather than handling.

Quality and lab results

Semax and its modified forms differ by small chemical changes, so confirming identity matters when comparing results across studies. Every PRIME batch is tested, and the certificate of analysis for each lot is published for researchers to review before use. See the PRIME COA and lab results page for current reports.

Research material is available as Semax, and the related anxiolytic peptide is available as Selank.

Related research

• Selank vs Semax: how the two Russian-developed regulatory peptides differ in origin and research focus
• Selank research guide: the tuftsin-derived peptide studied in anxiety and immune research
• DSIP research guide: a neuropeptide studied in sleep research

Semax FAQ

For laboratory research use only. Not for human consumption. Not a drug, food or cosmetic.